Neurodegenerative Disorder Therapeutics Market Report 2026

The neurodegenerative disorder therapeutics market size has grown strongly in recent years. It will grow from $21.66 billion in 2025 to $23.65 billion in 2026 at a compound annual growth rate (CAGR) of 9.2%. The growth in the historic period can be attributed to rising prevalence of neurodegenerative disorders, increasing aging population, limited treatment options, growing awareness about early diagnosis, expansion of hospital and neurology care infrastructure.

The neurodegenerative disorder therapeutics market size is expected to see strong growth in the next few years. It will grow to $34.13 billion in 2030 at a compound annual growth rate (CAGR) of 9.6%. The growth in the forecast period can be attributed to development of gene therapies, advancement in monoclonal antibody treatments, integration of ai-based diagnostics and monitoring, rising investment in clinical research and trials, expansion of personalized medicine and targeted therapeutics. Major trends in the forecast period include increasing adoption of neuroprotective and neurorestorative therapies, rising focus on symptom management and patient-centric care, growth in clinical trials for novel neurodegenerative drugs, expansion of personalized and targeted therapeutic approaches, integration of home care and remote monitoring solutions.

The growing investment in research and development for neurodegenerative disorder therapeutics is expected to drive the expansion of the neurodegenerative disorder therapeutics market in the coming years. Governments and organizations are increasing R&D investments in this area due to several factors, including the rising prevalence of neurodegenerative conditions, substantial unmet medical needs, significant economic and societal impacts, and broader global health priorities. For example, in March 2023, according to the Government of Canada, a Canada-based federal administration, the Canadian government announced an investment of $38.3 million in 2023 to support and advance research into neurodegenerative diseases. As a result, continued growth in research and development funding is expected to sustain momentum in the neurodegenerative disorder therapeutics market during the forecast period.

Major companies operating in the neurodegenerative disorder therapeutics market are concentrating on the development of innovative treatment approaches, such as prodrug formulations, to improve the bioavailability, effectiveness, and safety of therapies for Parkinson’s disease. Prodrugs are pharmacologically inactive compounds that are converted into active drugs within the body, enabling more controlled and sustained delivery of therapeutic agents. For instance, in January 2024, AbbVie Inc., a US-based biopharmaceutical company, launched PRODUODOPA (foslevodopa/foscarbidopa) in the European Union for individuals living with advanced Parkinson’s disease. This therapy uses a soluble prodrug combination to enable continuous delivery of levodopa, with the goal of reducing motor fluctuations and enhancing patients’ quality of life. The launch represents a notable advancement in the management of advanced Parkinson’s disease by providing an alternative to intermittent oral dosing and supporting better treatment adherence.

In March 2024, Bristol Myers Squibb Company, a US-based biopharmaceutical company, acquired Karuna Therapeutics Inc. for an undisclosed amount. Through this acquisition, Bristol Myers Squibb seeks to strengthen its neuroscience portfolio, accelerate the development of innovative therapies for neuropsychiatric disorders, and expand its research and commercial capabilities within central nervous system treatments. Karuna Therapeutics Inc. is a US-based clinical-stage biopharmaceutical company focused on developing novel therapies for neuropsychiatric diseases.

Major companies operating in the neurodegenerative disorder therapeutics market are Biogen Inc., Pfizer Inc., Novartis International AG, Sanofi S.A., Teva Pharmaceutical Industries Ltd., UCB S.A., F. Hoffmann-La Roche Ltd., ACADIA Pharmaceuticals Inc., H. Lundbeck A/S, Boehringer Ingelheim International GmbH, Merck Serono S.A., Orion Corporation, Mitsubishi Tanabe Pharma America, Allergan PLC, GlaxoSmithKline PLC, AbbVie Inc., Eli Lilly and Company, Celgene Corporation, Bayer Schering Pharma AG, AstraZeneca plc, Alector Inc., Yumanity Therapeutics Inc., Eisai Co. Ltd., Bristol Myers Squibb Company, Amylyx Pharmaceuticals Inc., Genentech Inc., AC Immune SA, Annexon Bioscience Inc., BioArctic Neuroscience AB, Cajal Neuroscience Inc., Cognito Therapeutics Inc., Grifols S.A., New Equilibrium Biosciences Inc., Prothena Corporation PLC, Tessera Therapeutics Inc., Vigil Neuroscience Inc.

North America was the largest region in the global neurodegenerative disorder therapeutics market in 2025. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the neurodegenerative disorder therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the neurodegenerative disorder therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the neurodegenerative disorder therapeutics market by increasing costs of imported biologics, gene therapy reagents, and advanced neuroprotective drugs. Segments like monoclonal antibodies and gene therapy products are most affected, particularly in North America and Europe where reliance on imports is high. This has resulted in higher treatment costs and potential delays in therapy availability. On the positive side, tariffs have incentivized domestic manufacturing, local R&D investment, and innovation in cost-effective neurodegenerative therapeutics.

The neurodegenerative disorder therapeutics market research report is one of a series of new reports that provides neurodegenerative disorder therapeutics market statistics, including neurodegenerative disorder therapeutics industry global market size, regional shares, competitors with a neurodegenerative disorder therapeutics market share, detailed neurodegenerative disorder therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the neurodegenerative disorder therapeutics industry. This neurodegenerative disorder therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Neurodegenerative disorder therapeutics refer to medications or gene therapies used to treat patients with neurodegenerative diseases by therapeutically addressing underlying pathogenic pathways through neuroprotection, neurorestoration, and symptom management.

The primary drug types in neurodegenerative disorder therapeutics include N-methyl-D-aspartate receptor antagonists, selective serotonin reuptake inhibitors, dopamine inhibitors, and others. Selective serotonin reuptake inhibitors are a class of medications commonly used to treat depression and certain other mental health conditions. These therapies are indicated for disorders such as Parkinson’s disease, Alzheimer’s disease, multiple sclerosis, Huntington’s disease, and others, and are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The neurodegenerative disorder therapeutics market includes revenues earned by entities by correction of pathogenic mechanisms, neuroprotection, neurorestoration, and symptom control. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.